Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial

Key facts

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Intervention

Postoperative radiotherapy(radiation)

Enrollment

190 target

Eligibility

18-70 years · All sexes

Timeline

2026 – 2031

Study locations (28)

• The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
• Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang, Beijing Municipality, China
• Fujian Cancer Hospital, Fuzhou, Fujian, China
• Cancer prevention and treatment center, sun yat-sen university, Guandong, Guangdong, China
• Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
• Renmin Hospital of Wuhan University, Wuhan, Hubei, China
• Hunan Provincial People's Hospital, Changsha, Hunan, China
• Hunan cancer hospital, Changsha, Hunan, China
• Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
• The First Hospital of Jilin University, Changchun, Jilin, China
• The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
• The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
• The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
• the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
• +13 more locations on ClinicalTrials.gov

Collaborators

Hunan Province Tumor Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sun Yat-Sen University Cancer Center · Shanghai Cancer Hospital, China · Tianjin Medical University Cancer Institute and Hospital · Xiangya Hospital of Central South University · Sichuan Cancer Hospital and Research Institute · Hunan Provincial People's Hospital · First Affiliated Hospital Xi'an Jiaotong University · The First Hospital of Jilin University · First Hospital of China Medical University · The Affiliated Hospital of Qingdao University · The First Affiliated Hospital of Bengbu Medical University · The First Affiliated Hospital of Dalian Medical University · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Renmin Hospital of Wuhan University · First Affiliated Hospital of Fujian Medical University · Jiangxi Provincial Cancer Hospital · Fujian Cancer Hospital · Zhejiang Cancer Hospital · First Affiliated Hospital of Wenzhou Medical University · Huzhou Center Hospital · The Second Affiliated Hospital of Dalian Medical University · Huashan Hospital · First Affiliated Hospital of Zhejiang University · Ningbo Medical Center Lihuili Hospital · The Second Affiliated Hospital of Harbin Medical University · Fudan University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the oral tongue

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07343271
  Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx
  University Hospital, Strasbourg, France
• RECRUITINGNCT06055868
  People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
  University of California, San Francisco
• RECRUITINGPHASE2, PHASE3NCT05893888
  Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma
  Privo Technologies
• RECRUITINGPHASE2NCT06485778
  A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
  Memorial Sloan Kettering Cancer Center
• RECRUITINGNCT06321003
  SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
  University of Palermo
• RECRUITINGPHASE3NCT05798793
  Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
  Hospital of Stomatology, Wuhan University
• ACTIVE NOT RECRUITINGPHASE2NCT06009861
  Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
  Peking University Hospital of Stomatology
• RECRUITINGPHASE2NCT05862168
  Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
  Weijia Fang, MD

See all trials for Squamous cell carcinoma of the oral tongue →